Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
Merritt WM, Kamat AA, Hwang JY, Bottsford-Miller J, Lu C, Lin YG, Coffey D, Spannuth WA, Nugent E, Han LY, Landen CN, Nick AM, Stone RL, Coffman K, Bruckheimer E, Broaddus RR, Gershenson DM, Coleman RL, Sood AK. Merritt WM, et al. Among authors: coffman k. Cancer Biol Ther. 2010 Dec 15;10(12):1306-14. doi: 10.4161/cbt.10.12.13582. Epub 2010 Dec 15. Cancer Biol Ther. 2010. PMID: 20948320 Free PMC article.
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK. Landen CN Jr, et al. Among authors: coffman kt. J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70. doi: 10.1093/jnci/djj414. J Natl Cancer Inst. 2006. PMID: 17077358
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, Kinch M, Kiener PA, Woods R, Gao C, Dall'Acqua W, Wu H, Coats S. Bruckheimer EM, et al. Among authors: coffman kt. Neoplasia. 2009 Jun;11(6):509-17, 2 p following 517. doi: 10.1593/neo.81578. Neoplasia. 2009. PMID: 19484140 Free PMC article.
Overexpression of the EphA2 tyrosine kinase in prostate cancer.
Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS. Walker-Daniels J, et al. Among authors: coffman k. Prostate. 1999 Dec 1;41(4):275-80. doi: 10.1002/(sici)1097-0045(19991201)41:4<275::aid-pros8>3.0.co;2-t. Prostate. 1999. PMID: 10544301
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Leow CC, Chesebrough J, Coffman KT, Fazenbaker CA, Gooya J, Weng D, Coats S, Jackson D, Jallal B, Chang Y. Leow CC, et al. Mol Cancer Ther. 2009 Aug;8(8):2131-41. doi: 10.1158/1535-7163.MCT-08-1038. Epub 2009 Aug 11. Mol Cancer Ther. 2009. PMID: 19671750
Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC.
Tu E, McGlinchey K, Wang J, Martin P, Ching SL, Floc'h N, Kurasawa J, Starrett JH, Lazdun Y, Wetzel L, Nuttall B, Ng FS, Coffman KT, Smith PD, Politi K, Cooper ZA, Streicher K. Tu E, et al. Among authors: coffman kt. JCI Insight. 2022 Feb 8;7(3):e142843. doi: 10.1172/jci.insight.142843. JCI Insight. 2022. PMID: 35132961 Free PMC article.
142 results